Novel recombinant RD2- and RD11-encoded Mycobacterium tuberculosis antigens are potential candidates for diagnosis of tuberculosis infections in BCG-vaccinated individuals

Chen, Jiazhen; Su, Xiaodi; Zhang, Ying; Wang, Sen; Shao, Linyun; Wu, Jing; Wang, Feifei; Zhang, Shu; Wang, Jiuling; Weng, Xinhua; Wang, Honghai; Zhang, Wenhong

doi:10.1016/j.micinf.2009.05.008

Cited by 33 publications

(31 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our result suggested that the sensitivity of the QFT-IT assay could be raised when it was used in combination with Rv1985c pool2 and Rv1985c pool4 , just as previous studies did (10,16,17). Though the additive effect on sensitivity was not statistically significant, the trend may be more obvious and relevant if tested on a broader scale.…”

Section: Differentiation Of M Tuberculosis Infection In Bcg-vaccinatedsupporting

confidence: 52%

“…PHA (2.5 g/ml) and saline were added as a positive control and a negative control, respectively. Peptide cocktails from ESAT-6, including ESAT-6 from residues 1 to 20 (ESAT-6 [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] ), ESAT-6 42-65 , ESAT-6 52-75 , and ESAT-6 72-95 , were selected according to some other research (23,24) and tested as controls to evaluate the diagnostic performance of the selected peptide pools. On the basis of a dose-response curve ranging from 0 to 20 g/ml, the working concentration of the peptide mixtures was determined at the concentration with the strongest response, which was 1 g/ml per peptide.…”

Section: Methodsmentioning

confidence: 99%

“…The proteins encoded in the regions of differences (RDs) of M. tuberculosis have become the most promising candidates as diagnostic antigens. Our previous study demonstrated that recombinant antigens of Rv1985c and Rv3425 had great potential for specific immune-based diagnosis of TB infection in the BCG-vaccinated population (16,17). In this study, 25-amino-acid-long peptides covering the whole length of the two antigens were first tested for their ability to stimulate IFN-␥ release.…”

Section: Differentiation Of M Tuberculosis Infection In Bcg-vaccinatedmentioning

confidence: 99%

“…To search for novel antigens with diagnostic potential, we screened several recombinant RD2 and RD11 antigens for their ability to induce an antigen-specific T-cell response and found that RD2 antigen Rv1985c and RD11 antigen Rv3425 have good diagnostic potential (16,17). Rv1985c is a putative chromosome replication initiation inhibitor protein which was specifically recognized by both cellular and humoral responses from patients with TB (17).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Mycobacterium tuberculosis Region of Difference (RD) 2 Antigen Rv1985c and RD11 Antigen Rv3425 Have the Promising Potential To Distinguish Patients with Active Tuberculosis from M. bovis BCG-Vaccinated Individuals

Wang

Chen

Zhang

et al. 2013

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

e Antigens encoded in the region of difference (RD) of Mycobacterium tuberculosis constitute a potential source of specific immunodiagnostic antigens for distinguishing tuberculosis (TB) infection from BCG vaccination. We evaluated the diagnostic potential of specific T-cell epitopes selected from two immunodominant antigens, Rv1985c and Rv3425, from RD2 and RD11, respectively, on the basis of epitope mapping, in TB patients and BCG-vaccinated healthy individuals. Using a whole-blood gamma interferon release assay, a wide array of epitopes was recognized on both Rv1985c and Rv3425 in TB patients. Those epitopes that could specifically discriminate TB infection from BCG vaccination were carefully selected, and the most promising peptide pools from Rv1985c showed a sensitivity of 53.9% and a specificity of 95.5%. When the novel specific peptides from Rv1985c joined the diagnostic antigens in the QuantiFERON-TB Gold In-Tube (QFT-IT) assay, the sensitivity was increased from 86.4% to 96.2%, with no drop in specificity. These results indicate that the peptide pools selected from Rv1985c and Rv3425 have the potential to diagnose TB infection by a method that may be routinely used in clinical laboratories.

show abstract

Section: Differentiation Of M Tuberculosis Infection In Bcg-vaccinatedsupporting

confidence: 52%

Section: Methodsmentioning

confidence: 99%

Section: Differentiation Of M Tuberculosis Infection In Bcg-vaccinatedmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Mycobacterium tuberculosis Region of Difference (RD) 2 Antigen Rv1985c and RD11 Antigen Rv3425 Have the Promising Potential To Distinguish Patients with Active Tuberculosis from M. bovis BCG-Vaccinated Individuals

Wang

Chen

Zhang

et al. 2013

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Rv1989c , Rv1978 , Rv1981c , and Rv1985c also encoded by RD2, were investigated for T-cell-based diagnosis of TB [23,29,30]. The loss of RD2 has an important influence on the protective efficacy of different BCG sub-strains.…”

Section: Attenuation Mechanismsmentioning

confidence: 99%

BCG vaccine in Korea

Joung

Ryoo

2013

Clin Exp Vaccine Res

View full text Add to dashboard Cite

The anti-tuberculosis Bacille de Calmette et Guérin (BCG) vaccine was developed between 1905 and 1921 at Pasteur Institutes of Lille in France, and was adopted by many countries. BCG strains comprise natural mutants of major virulence factors of Mycobacterium tuberculosis and that BCG sub-strains differ markedly in virulence levels. The tuberculosis became endemic in Korea after the Korean War (1950s). The BCG strain, which was donated by Pasteur Institutes, was brought to Korea in 1955, and the first domestic BCG vaccine was produced by the National Defense Research Institute (NDRI), current Korea Centers for Disease Control and Prevention (KCDC), in 1960. Since 1987, BCG manufacture work was handed over to the Korean Institute of Tuberculosis (KIT), the freeze-dried BCG vaccine was manufactured at a scale required to meet the whole amount of domestic consumption. However, since 2006, the manufacture of BCG vaccine suspended and the whole amount of BCG was imported at this point of time. Now KIT is planning to re-produce the BCG vaccine in Korea under the supervision of KCDC, this will be render great role to National Tuberculosis Control Program (NTP) and provide initiating step for developing new tuberculosis vaccines in Korea.

show abstract

PPE57 induces activation of macrophages and drives Th1-type immune responses through TLR2

Yang

Huang

et al. 2015

J Mol Med

View full text Add to dashboard Cite

show abstract

Novel recombinant RD2- and RD11-encoded Mycobacterium tuberculosis antigens are potential candidates for diagnosis of tuberculosis infections in BCG-vaccinated individuals

Cited by 33 publications

References 31 publications

Mycobacterium tuberculosis Region of Difference (RD) 2 Antigen Rv1985c and RD11 Antigen Rv3425 Have the Promising Potential To Distinguish Patients with Active Tuberculosis from M. bovis BCG-Vaccinated Individuals

Mycobacterium tuberculosis Region of Difference (RD) 2 Antigen Rv1985c and RD11 Antigen Rv3425 Have the Promising Potential To Distinguish Patients with Active Tuberculosis from M. bovis BCG-Vaccinated Individuals

BCG vaccine in Korea

PPE57 induces activation of macrophages and drives Th1-type immune responses through TLR2

Contact Info

Product

Resources

About